中国实用外科杂志
• 专题笔谈 • 上一篇 下一篇
刘 彤,赵智成
出版日期:
发布日期:
Online:
Published:
摘要:
原发性胃肠间质瘤(GIST)完整手术切除后出现复发是临床常见问题,包括局部原位复发、腹腔播散种植和远隔脏器转移3种类型。伊马替尼等靶向药物的问世改善了复发性GIST的治疗方式和结局。应用影像学手段精确评估复发病灶状态,仔细了解病人服药情况和一般身体状况有助于科学选择治疗策略。伊马替尼是复发性GIST的首选治疗,但很少出现病理学完全缓解,连续治疗应持续到病人无法耐受或疾病出现进展。结合靶向治疗,适宜的外科手术切除复发或转移病灶能给病人带来生存获益。
关键词: 胃肠间质瘤, 伊马替尼, 靶向治疗
Abstract:
Strategy and evaluation of diagnosis and treatment on recurrent gastrointestinal stromal tumor LIU Tong, ZHAO Zhi-cheng. Department of General Surgery, Tianjin Medical University General Hospital and Tianjin Institute of General Surgery,Tianjin 300052, China Corresponding author: LIU Tong, E-mail: liutonga@126.com Abstract The recurrence following complete resection of primary gastrointestinal stromal tumor (GIST) is a common clinical problem, including three types which are local recurrence in situ, peritoneal dissemination and distant organ metastases. As targeted therapy, the availability of imatinib has altered the treatment approach and improved the outcome of recurrent GIST. Accurate assessment of recurrent lesions using imaging modalities, careful understanding of patient’s medication administrating and general physical condition could be helpful for the choice of therapeutic strategy scientifically. Imatinib is the first line treatment for recurrent GIST and should be administrated continually until patient intolerant or disease progresses because of rare pathologic complete respond. Combined with targeted therapy, appropriate surgical intervention to resection of recurrent or metastatic focus can bring a survival benefit to the patients.
Key words: gastrointestinal stromal tumor, imatinib, targeted therapy
刘 彤,赵智成. 复发性胃肠间质瘤诊治对策及评价[J]. 中国实用外科杂志, DOI: 10.7504/CJPS.ISSN1005-2208.2015.04.17.
0 / 推荐
导出引用管理器 EndNote|Ris|BibTeX
链接本文: https://www.zgsyz.com/zgsywk/CN/10.7504/CJPS.ISSN1005-2208.2015.04.17
https://www.zgsyz.com/zgsywk/CN/Y2015/V35/I04/407